174 results
Page 2 of 9
8-K
EX-99.2
vsxe5u9e0l6p8xr7
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
vsxfz4kucd9fotl4m
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
S-8
w198to19 fwx1
7 Nov 23
Registration of securities for employees
4:31pm
8-K
EX-99.1
kjc prni6
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-1.1
ejf 9fva1pxjkialw7x5
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
w874d95i6
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
scnx eri2
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
mtcb8 9z0zk5z
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
q0ls6 hwa1
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.2
r0t2lth8ji v6aupm9
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
9m236
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
r7zckwrq dpz8b2
4 May 23
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
n4usv lg19
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
s4y8xt0a
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
S-8
e13zljb9hggv rhn3
14 Nov 22
Registration of securities for employees
8:48am